The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Nuvo Research Obtains Additional US Patent for Pennsaid® 2%

06-Sep-2012 | Source : | Visits : 8247
MISSISSAUGA, Ontario, Canada - Nuvo Research Inc. today announced in a press release that the United States Patent Office has issued United States Patent No. 8,252,838 relating to compositions and methods of using PENNSAID® (diclofenac sodium topical solution) 2.0% w/w (PENNSAID 2% Patent). The patent expires on April 21, 2028.

Nuvo’s US licensing partner, Mallinckrodt Inc. (Mallinckrodt), the pharmaceuticals business of Covidien, has advised Nuvo that the US Food and Drug Administration (FDA) had accepted a New Drug Application (NDA) for PENNSAID (diclofenac sodium topical solution) 2.0% w/w for review and set a Prescription Drug User Fee Act (PDUFA) date of March 4, 2013 for action on the submission. Mallinckrodt will take the necessary steps to have the new patent listed in the FDA Orange Book upon FDA approval. 

“We are very pleased that we have been able to secure additional patent protection for PENNSAID 2%,” said Tina Loucaides, Nuvo’s Vice President and General Counsel. “This patent, together with our recently announced method of use patent for PENNSAID and PENNSAID 2% gives us a strong patent portfolio that will support the PENNSAID franchise.”

PENNSAID 2% is the follow-on product to original PENNSAID, a topical non-steroidal anti-inflammatory drug (NSAID).

Nuvo Research is a publicly traded, Canadian specialty pharmaceutical company, headquartered in Mississauga, Ontario. The Company is building a portfolio of products for the treatment of pain through internal research and development and by in-licensing and acquisition. 

Related Articles